Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Alzheimer's disease
Alzheimer's disease
Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy
BioPharma Dive
Sun, 01/8/23 - 10:04 pm
Eisai
Biogen
drug pricing
Leqembi
Alzheimer's disease
lecanemab
FDA approves Alzheimer’s drug from Eisai, Biogen in closely watched decision
BioPharma Dive
Fri, 01/6/23 - 03:40 pm
Eisai
Biogen
lecanemab
Leqembi
Alzheimer's disease
FDA
10 clinical trials to watch in the first half of 2023
BioPharma Dive
Tue, 01/3/23 - 10:57 am
clinical trials
Alzheimer's disease
obesity
Huntington's disease
M&A
AstraZeneca
Daiichi Sankyo
Nimbus Therapeutics
Takeda
Eli Lilly
Sanofi
Regeneron
Moderna Therapeutics
Gilead Sciences
Pfizer
Roivant
Alnylam
uniQure
Biogen, FDA's inappropriate Aduhelm coordination detailed in blistering congressional report
Fierce Pharma
Fri, 12/30/22 - 10:50 am
Biogen
Aduhelm
Alzheimer's disease
FDA
US Congress
Eisai and Biogen’s latest Alzheimer’s drug needs to be cheaper than the last one, analysts say
Stat
Thu, 12/22/22 - 11:10 am
Biogen
Eisai
Alzheimer's disease
drug pricing
ICER
lecanemab
3rd patient death potentially tied to Eisai's Alzheimer's drug reported
Fierce Biotech
Thu, 12/22/22 - 11:05 am
Biogen
Eisai
Alzheimer's disease
clinical trials
patient deaths
lecanemab
Has This Top Pharma Company Found Its Next Billion-Dollar Product?
Motley Fool
Thu, 12/22/22 - 10:46 am
Eli Lilly
Alzheimer's disease
Ahead of lecanemab decision, Alzheimer's groups petition CMS to reverse coverage policy
Endpoints
Wed, 12/21/22 - 11:31 am
Biogen
FDA
Alzheimer's disease
CMS
clinical trials
Synaptogenix reports disappointing data from Phase II Alzheimer’s trial
Clinical Trials Arena
Mon, 12/19/22 - 11:08 am
Synaptogenix
clinical trials
NIH
Alzheimer's disease
Bryostatin-1
Regeneron's Yancopoulos draws boos as he touts pharma innovation over cost considerations
Fierce Biotech
Thu, 12/8/22 - 11:22 pm
Regeneron
George Yancopoulos
innovation
Alzheimer's disease
Alzheimer’s disease drug development: three major questions for 2023
Clinical Trials Arena
Wed, 12/7/22 - 11:34 pm
Alzheimer's disease
drug development
CTAD 2022 – Lexeo takes baby steps towards an Alzheimer’s gene therapy
EP Vantage
Sun, 12/4/22 - 01:07 pm
Lexeo
Alzheimer's disease
CTAD
gene therapy
Athira’s Alzheimer’s Therapy Climbs Ranks in a Competitive Space
BioSpace
Fri, 12/2/22 - 11:08 am
Athira Pharma
Alzheimer's disease
fosgonimeton
IGC starts clinical trial of drug candidate to treat agitation in dementia
Clinical Trials Arena
Fri, 12/2/22 - 11:00 am
IGC
clinical trials
IGC-AD1
Alzheimer's agitation
Alzheimer's disease
Lilly’s Donanemab Shines vs. Aduhelm in First Active Comparator Study
BioSpace
Thu, 12/1/22 - 07:10 pm
Eli Lilly
donanemab
clinical trials
Aduhelm
Biogen
Alzheimer's disease
CTAD 2022 – lecanemab data hold up, with a big but
EP Vantage
Thu, 12/1/22 - 07:01 pm
Biogen
Eisai
Alzheimer's disease
CTAD
lecanemab
clinical trials
J&J unit, happy with AC Immune Alzheimer's work, moves 1 of 2 shots to next step
Fierce Biotech
Thu, 12/1/22 - 10:33 am
JNJ
AC Immune
Alzheimer's disease
Janssen
vaccines
ACI-35.030
CTAD 2022 – gantenerumab’s shortcomings keep amyloid hypothesis alive
EP Vantage
Thu, 12/1/22 - 10:28 am
Roche
clinical trials
CTAD
Alzheimer's disease
gantenerumab
What to make of Eisai and Biogen’s latest Alzheimer’s drug data
BioPharma Dive
Tue, 11/29/22 - 10:58 pm
Biogen
Eisai
Alzheimer's disease
lecanemab
Eisai, Biogen rocked by 2nd lecanemab death report ahead of Alzheimer's data reveal
Fierce Biotech
Mon, 11/28/22 - 07:51 pm
Biogen
Eisai
clinical trials
patient death
lecanemab
Alzheimer's disease
Pages
« first
‹ previous
…
4
5
6
7
8
9
10
11
12
…
next ›
last »